Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors.
Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million
Pulse Biosciences Q1 Earnings Call Highlights
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
Pulse Biosciences, Inc. (PLSE) Q1 2026 Earnings Call Transcript
Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
Pulse Biosciences, Inc. (PLSE) Shareholder/Analyst Call Transcript
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026
Pulse Biosciences' nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting
Pulse Biosciences to Host Analyst Event on April 25, 2026
Argo Wealth Advisory LLC Makes New $387,000 Investment in Pulse Biosciences, Inc $PLSE
Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study
Pulse Biosciences Strengthens Executive Leadership Team
Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation
Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference
PLSE Accelerates Cardiac Catheter Program After Breakthrough AFib Data
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Pulse Biosciences' nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting
Kevin Patrick Danahy Sells 5,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference
Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript
Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Beats Revenue Estimates
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results
PLSE Shares Positive First-in-Human nPulse Cardiac Catheter Data
What's Going With Pulse Biosciences Stock On Monday?
Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up – Here’s Why
Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium
Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026
Pulse Biosciences' nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium
Here Are Friday’s Top Wall Street Analyst Research Calls: Broadcom, Circle Internet, Kenvue, Medtronic, Sandisk, Southwest Airlines, Spotify, and More
Pulse Biosciences, Inc. (PLSE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium
Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial
Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation
PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor
Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology
Critical Contrast: Pulse Biosciences (NASDAQ:PLSE) vs. ENDRA Life Sciences (NASDAQ:NDRA)
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences, Inc. (PLSE) Q3 2025 Earnings Call Transcript
Pulse Biosciences, Inc (PLSE) Reports Q3 Loss, Lags Revenue Estimates